Search

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2004.10.045 Byline: Cesare de Gregorio, Antonio Micari, Patrizia Grimaldi, Thanjavur Bragadeesh, Francesco Arrigo, Sebastiano Coglitore Abstract: The assessment of coronary flow velocity is becoming crucial in the diagnosis and management of several cardiac dysfunctions and conventional Doppler echocardiography is currently the technique most widely used for detecting their abnormalities noninvasively. Author Affiliation: Clinical and Experimental Department of Medicine and Pharmacology, Cardiology and Cardiac Rehabilitative Unit, University Hospital of Messina, Messina, Italy Article History: Received 5 April 2004; Accepted 15 October 2004 Article Note: (miscellaneous) Drs. de Gregorio and Micari equally contributed to the study.

Background Left atrial (LA) volume is an important marker of cardiac dysfunction and cardiovascular outcome in heart failure (HF), but LA function is rarely measured. Methods Left atrial emptying function (LAEF), its clinical associations and prognostic value was studied in outpatients referred with suspectedHFwhowere in sinus rhythm and had cardiac magnetic resonance imaging (CMRI). Heart failurewas defined as relevant symptoms and signs with either a left ventricular ejection fraction (LVEF) <50% or amino-terminal pro-B-type natriuretic peptide (NTproBNP) >400 pg/mL (or >125 pg/mL if taking loop diuretics). Results Of 982 patients, 664 fulfilled the HF criteria and were in sinus rhythm. The median (interquartile range, IQR) LAEF was 42 (31-51)% and 55 (48-61)% in patients with and without HF (P < 0.001). Patients with HF in the lowest quartile of LAEF (23%; IQR: 17-28%) had lower LV and right ventricular (RV) EF, and greater LV and RV mass and higher plasma NTproBNP than those in the highest quartile of LAEF (56%; IQR: 53-61%). Log[LAEF] and log[NTproBNP] were inversely correlated (r = -0.410, P < 0.001). During a median follow-up of 883 (IQR: 469-1626) days, 394 (59%) patients with HF died or were admitted with HF and 101 (15%) developed atrial fibrillation (AF). In a multivariable Cox model, increasing LAEF, but not LVEF, was independently associated with survival (HR for 10% change: 0.81 (95%CI: 0.73-0.90), P = <0.001). Increasing age and decreasing LAEF predicted incident AF. Conclusions In patients with HF, LAEF predicts adverse outcome independently of other measures of cardiac dysfunction. [ABSTRACT FROM AUTHOR]

Small fistulae between coronary arteries and the pulmonary artery are common, but abnormal vascular communications between the coronary arteries and other cardiac structures are rare. They were first described by Krause in 1865. We report two cases of fistulous connexions between the circumflex coronary artery and the coronary sinus. [ABSTRACT FROM AUTHOR]

Aims: Regadenoson is comparable to adenosine in pharmacologic radionuclide stress tests but has not been studied with stress myocardial contrast echocardiography. This study assessed the haemodynamic profile and ability of regadenoson, a novel selective A(2A) receptor agonist, to detect coronary artery stenosis during myocardial contrast echocardiography., Methods and Results: Myocardial contrast echocardiography was performed to measure myocardial blood volume, myocardial blood flow velocity, and total regional myocardial blood flow before and after administration of regadenoson (5 µg kg(-1), 10 s bolus) in 10 open-chest dogs with mild-to-moderate coronary stenosis that was not flow limiting at rest. Regadenoson decreased blood pressure but did not change heart rate. It increased coronary blood flow significantly (P < 0.05) for 30 min, which was attenuated in proportion to coronary stenosis severity. Whereas myocardial blood volume maximally increased by 0.5-0.75-fold in the control region, it did not change in the region supplied by the non-flow limiting stenosis. Perfusion defects were visually and quantitatively detectable for as long as 10 min after administration of regadenoson. No arrhythmias were noted with regadenoson either prior to or during myocardial contrast echocardiography., Conclusion: Regadenoson can be used as a vasodilator stress agent with myocardial contrast echocardiography to detect the presence of physiologically significant coronary stenosis. The optimum time for image acquisition was 3-10 min after drug administration.